SEC Form 4
BeOne Medicines Ltd. (ONC) insider trading
In the 12 months to Oct 26, 2026, 13 ONC insiders reported open-market sales of $380.1M across 52 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $380.1M
- 52 filings · 13 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 22 of 52
- $363.6M of $380.1M sold (96%)
Who traded ONC, and when
- Sale
- Sale, pre-arranged (10b5-1)
ONC daily close from Oct 27, 2025 to Oct 26, 2026, between $260.27 and $386.46, last $371.70. 52 sale and 0 purchase filings by 13 insiders, marked at their filing dates. John Oyler, Chief Executive Officer: sold $327.9M across 11 filings, first filed Dec 17, 2025, last Aug 12, 2026. Xiaodong Wang, Director: sold $35.6M across 3 filings, first filed Sep 10, 2026, last Oct 15, 2026. Xiaobin Wu, President and COO: sold $8.8M across 7 filings, first filed Nov 14, 2025, last Aug 27, 2026. Chan Henry Lee, SVP, General Counsel: sold $4.6M across 15 filings, first filed Nov 14, 2025, last Oct 2, 2026. Lai Wang, President, Global Head of R&D: sold $1.2M across 4 filings, first filed Jun 10, 2026, last Jun 25, 2026. Corazon (Corsee) D. Sanders, Director: sold $961.2K across 2 filings, first filed Dec 1, 2025, last May 27, 2026. 7 others: sold $1.1M across 10 filings, first filed May 27, 2026, last Sep 3, 2026.
Largest mark · tap a row for others
John Oyler · Chief Executive Officer
Filing 1 of 4 within a week · $172,398,736 total
Sale $18,256,808
60,218 ADS
Filed Jul 14, 2026 · traded Jul 10
Pre-arranged (10b5-1) · close on filing date $306.56
John Oyler · Chief Executive Officer
Chief Executive Officer
$327.9M soldXiaodong Wang · Director
Director
$35.6M soldXiaobin Wu · President and COO
President and COO
$8.8M soldChan Henry Lee · SVP, General Counsel
SVP, General Counsel
$4.6M soldLai Wang · President, Global Head of R&D
President, Global Head of R&D
$1.2M soldCorazon (Corsee) D. Sanders · Director
Director
$961.2K sold7 others
Combined, one mark per week
$1.1M soldOpen-market trades
52 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| John Oyler | Chief Executive Officer | $327.9M | — | 11 | 99% of sales | |
| Xiaodong Wang | Director | $35.6M | — | 3 | 100% of sales | |
| Xiaobin Wu | President and COO | $8.8M | — | 7 | 1% of sales | |
| Chan Henry Lee | SVP, General Counsel | $4.6M | — | 15 | 82% of sales | |
| Lai Wang | President, Global Head of R&D | $1.2M | — | 4 | — | |
| Corazon (Corsee) D. Sanders | Director | $961.2K | — | 2 | — | |
| Aaron Rosenberg | Chief Financial Officer | $524.4K | — | 2 | — | |
| Felix Baker | Director | $196.6K | — | 1 | — | |
| Titus B. Ball | Principal Accounting Officer | $127.3K | — | 3 | — | |
| Margaret Dugan | Director | $65.6K | — | 1 | — | |
| Alessandro Riva | Director | $65.6K | — | 1 | — | |
| Qingqing Yi | Director | $65.6K | — | 1 | — | |
| Julian Baker | Director | $65.4K | — | 1 | — |
| Filed | Insider | Type | Shares | Value | Held after | Source |
|---|---|---|---|---|---|---|
traded | Xiaodong Wang Director | SalePre-arranged (10b5-1) | 31,027 ADS | $10.9M | 1,260 | |
traded | Chan Henry Lee SVP, General Counsel | SalePre-arranged (10b5-1) | 1,115 ADS | $418.1K | 0 | |
traded | Xiaodong Wang Director | SalePre-arranged (10b5-1) | 31,028 ADS | $11.3M | 24,228 | |
traded | Xiaodong Wang Director | SalePre-arranged (10b5-1) | 38,287 ADS | $13.4M | 3,238 | |
traded | Titus B. Ball Principal Accounting Officer | Sale | 132 ADS | $47.0K | 0 | |
traded | Xiaobin Wu President and COO | SalePre-arranged (10b5-1) | 280 ADS | $106.4K | 0 | |
traded | Chan Henry Lee SVP, General Counsel | SalePre-arranged (10b5-1) | 2,666 ADS | $959.8K | 0 | |
traded | John Oyler Chief Executive Officer | SalePre-arranged (10b5-1) | 240,810 ADS | $86.5M | 50,397 | |
traded | Aaron Rosenberg Chief Financial Officer | Sale | 1,157 ADS | $361.8K | 0 | |
traded | Chan Henry Lee SVP, General Counsel | Sale | 1,044 ADS | $337.9K | 0 | |
traded | Chan Henry Lee SVP, General Counsel | SalePre-arranged (10b5-1) | 1,669 ADS | $542.4K | 0 | |
traded | John Oyler Chief Executive Officer | SalePre-arranged (10b5-1) | 109,713 ADS | $34.6M | 25,989 | |
traded | John Oyler Chief Executive Officer | SalePre-arranged (10b5-1) | 283,154 ADS | $89.4M | 15,189 | |
traded | John Oyler Chief Executive Officer | SalePre-arranged (10b5-1) | 64,628 ADS | $20.2M | 15,706 | |
traded | John Oyler Chief Executive Officer | SalePre-arranged (10b5-1) | 60,218 ADS | $18.3M | 43,138 | |
traded | John Oyler Chief Executive Officer | SalePre-arranged (10b5-1) | 145,861 ADS | $44.6M | 0 | |
traded | Chan Henry Lee SVP, General Counsel | SalePre-arranged (10b5-1) | 664 ADS | $200.8K | 0 | |
traded | John Oyler Chief Executive Officer | Sale | 3,410 ADS | $933.6K | 320 | |
traded | Xiaobin Wu President and COO | Sale | 1,292 ADS | $356.9K | 0 | |
traded | Lai Wang President, Global Head of R&D | Sale | 1,068 ADS | $295.6K | 0 | |
traded | John Oyler Chief Executive Officer | Sale | 3,693 ADS | $980.7K | 0 | |
traded | Xiaobin Wu President and COO | Sale | 1,357 ADS | $362.0K | 0 | |
traded | Lai Wang President, Global Head of R&D | Sale | 1,169 ADS | $310.2K | 0 | |
traded | Chan Henry Lee SVP, General Counsel | Sale | 590 ADS | $156.9K | 0 | |
traded | John Oyler Chief Executive Officer | Sale | 1,949 ADS | $501.4K | 1,208 | |
traded | Titus B. Ball Principal Accounting Officer | Sale | 169 ADS | $43.5K | 120 | |
traded | Xiaobin Wu President and COO | Sale | 626 ADS | $163.5K | 0 | |
traded | Lai Wang President, Global Head of R&D | Sale | 756 ADS | $197.3K | 0 | |
traded | Chan Henry Lee SVP, General Counsel | Sale | 428 ADS | $110.3K | 0 | |
traded | Aaron Rosenberg Chief Financial Officer | Sale | 631 ADS | $162.6K | 0 | |
traded | John Oyler Chief Executive Officer | Sale | 4,940 ADS | $1.3M | 0 | |
traded | Titus B. Ball Principal Accounting Officer | Sale | 136 ADS | $36.9K | 36 | |
traded | Xiaobin Wu President and COO | Sale | 1,484 ADS | $399.7K | 0 | |
traded | Lai Wang President, Global Head of R&D | Sale | 1,367 ADS | $368.2K | 0 | |
traded | Chan Henry Lee SVP, General Counsel | Sale | 871 ADS | $235.5K | 160 | |
traded | Qingqing Yi Director | Sale | 235 ADS | $65.6K | 0 | |
traded | Felix Baker Director | Sale | 8,255 ordinary shares | $196.6K | 142,570 | |
traded | Julian Baker Director | Sale | 2,743 ordinary shares | $65.4K | 145,326 | |
traded | Corazon (Corsee) D. Sanders Director | Sale | 212 ADS | $65.6K | 0 | |
traded | Alessandro Riva Director | Sale | 212 ADS | $65.6K | 0 | |
traded | Margaret Dugan Director | Sale | 212 ADS | $65.6K | 0 | |
traded | Chan Henry Lee SVP, General Counsel | SalePre-arranged (10b5-1) | 332 ADS | $103.2K | 0 | |
traded | Chan Henry Lee SVP, General Counsel | SalePre-arranged (10b5-1) | 332 ADS | $103.4K | 0 | |
traded | Chan Henry Lee SVP, General Counsel | SalePre-arranged (10b5-1) | 341 ADS | $102.3K | 0 | |
traded | Chan Henry Lee SVP, General Counsel | SalePre-arranged (10b5-1) | 1,660 ADS | $580.2K | 0 | |
traded | Chan Henry Lee SVP, General Counsel | SalePre-arranged (10b5-1) | 664 ADS | $220.3K | 0 | |
traded | John Oyler Chief Executive Officer | SalePre-arranged (10b5-1) | 100,000 ADS | $30.7M | 2,013 | |
traded | Chan Henry Lee SVP, General Counsel | SalePre-arranged (10b5-1) | 664 ADS | $213.6K | 0 | |
traded | Corazon (Corsee) D. Sanders Director | Sale | 2,627 ADS | $895.5K | 0 | |
traded | Xiaobin Wu President and COO | Sale | 3,991 ADS | $1.5M | 0 | |
traded | Xiaobin Wu President and COO | Sale | 16,009 ADS | $5.8M | 0 | |
traded | Chan Henry Lee SVP, General Counsel | SalePre-arranged (10b5-1) | 996 ADS | $347.8K | 332 |
Shares are as filed (ordinary shares or ADS); values are as converted to US$ in the filing.
GET /stocks/filings/vX/form-4?tickers=ONC&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"BGNE",
"ONC"
],
"issuer_cik": "0001651308",
"owner_cik": "0001662982",
"accession_number": "0001662982-26-000006",
"form_type": "4",
"filing_date": "2026-10-15",
"period_of_report": "2026-10-13",
"issuer_name": "BeOne Medicines Ltd.",
"issuer_trading_symbol": "ONC",
"owner_name": "Wang Xiaodong",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "American Depositary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-13",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 10361,
"transaction_price_per_share": 350.4741,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 13499,
"transaction_value": 3631262.1501,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F4",
"description": "Each American Depositary Share represents 13 Ordinary Shares."
},
{
"id": "F5",
"description": "The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026."
},
{
"id": "F7",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.98 to $350.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price."
}
]
},
{
"tickers": [
"BGNE",
"ONC"
],
"issuer_cik": "0001651308",
"owner_cik": "0001662982",
"accession_number": "0001662982-26-000006",
"form_type": "4",
"filing_date": "2026-10-15",
"period_of_report": "2026-10-13",
"issuer_name": "BeOne Medicines Ltd.",
"issuer_trading_symbol": "ONC",
"owner_name": "Wang Xiaodong",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "American Depositary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-13",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 5681,
"transaction_price_per_share": 351.3958,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 7818,
"transaction_value": 1996279.5398000001,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F4",
"description": "Each American Depositary Share represents 13 Ordinary Shares."
},
{
"id": "F5",
"description": "The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026."
},
{
"id": "F8",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.98 to $351.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 78 records
- Option exercises48 records
- Grants and awards27 records
- Gifts3 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has BeOne Medicines Ltd.'s CEO sold stock?
Yes. John Oyler (CEO) sold 1,018,376 shares ($327.9M) between Dec 2025 and Aug 2026, $324.1M of it under a pre-arranged 10b5-1 plan.
How current is ONC’s insider data?
These are ONC Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ONC insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ONC every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.